FDA approves tucatinib as chemotherapy-free maintenance for advanced HER2-positive breast cancer
- On 7 October 2026 the FDA approved Tukysa (tucatinib) with trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer.
- Tucatinib maintenance starts after induction treatment that includes chemotherapy.
- In HER2CLIMB-05, median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo.
- Tucatinib carries a boxed warning for liver toxicity, and diarrhoea affected 73% of patients.
The US Food and Drug Administration approved Tukysa (tucatinib), from Pfizer subsidiary Seagen, on 7 October 2026 in combination with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
The trial
Approval rests on HER2CLIMB-05, a randomized double-blind trial of 654 patients whose disease had not progressed after 4–8 cycles of trastuzumab, pertuzumab and a taxane, including patients with brain metastases. They received tucatinib 300 mg or placebo twice daily with the two antibodies, without chemotherapy.
Also read: Breast Cancer Awareness Month: WHO launches training manual to expand early breast cancer care
Results
Median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo, a 36% lower risk of progression or death. Overall survival data are immature, and progression was assessed by investigators.
Safety
Tucatinib carries a boxed warning for hepatotoxicity; one patient died of drug-induced liver injury. Liver tests are needed every 2 weeks for the first 2 months, then every 3 weeks. Diarrhoea occurred in 73% of patients, severe (grade 3) in 6%.
Sources: US Food and Drug Administration (FDA), AJMC, CURE
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What did the FDA approve for tucatinib?
On 7 October 2026 the FDA approved tucatinib (Tukysa) with trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction treatment.
What does tucatinib maintenance mean?
Tucatinib maintenance is given after chemotherapy-based induction ends, to keep HER2-positive breast cancer under control longer without chemotherapy.
How long did tucatinib keep the disease in check?
In HER2CLIMB-05, median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo.
What are the main risks of tucatinib?
Tucatinib has a boxed warning for liver toxicity, which can be fatal, so liver tests are needed regularly; it also often causes diarrhoea.
Does tucatinib maintenance extend overall survival?
The effect of tucatinib maintenance on overall survival is not yet known because HER2CLIMB-05 survival data are still immature.



